Callan JMB Plans $28 Million in Pharmaceutical Equipment in Alabama
Key Facts
Callan JMB signed an initial purchase order for pharmaceutical manufacturing equipment planned for installation at the Atlas campus in Alabama, under an equipment program worth about $28 million. The company said in a statement distributed through GlobeNewswire on October 8, 2026, that it expects to make a $500,000 down payment under the plan. The announced value covers equipment intended for pharmaceutical manufacturing at the campus, while the down payment remains among the company's anticipated payments. The company described it as a "$500,000 down payment toward approximately $28 million" in its update on pharmaceutical manufacturing progress. The project includes a planned manufacturing facility called Marion 9, spanning 90,000 square feet, according to Investing.com.
The Atlas campus is in Marion, Alabama, according to the project page on Callan JMB's website. The company lists pharmaceutical manufacturing among the campus's target activities, alongside the production of active pharmaceutical ingredients used in the industry. The target activities also include healthcare infrastructure and cold-chain logistics, among the operations the company outlines for the site. Callan JMB provides emergency preparedness and response services, as well as specialized packaging and product fulfillment, according to its business description on its official website. These activities serve sectors including pharmaceuticals, diagnostics and healthcare logistics, which the company identifies as part of its services for the life sciences industries.
The company had expected the Atlas campus to generate revenue from subleasing, facilities management and logistics, according to an earlier project presentation reported by Investing.com. It also listed professional services among the activities from which it intends to generate revenue at the campus, alongside management and leasing operations. Regarding its agreement with Alabama State University, management expects the agreement to generate more than $414 million in revenue over its initial 5-year term. The company said on its website that management expects the agreement "could generate revenue exceeding $414 million over the initial 5-year term." Callan JMB also intends to seek designation of the site as a subzone within the foreign-trade zones system, according to the plan reported by Investing.com.
The disruption to U.S. intravenous fluid supplies traces back to a crisis following Hurricane Helene, when a Baxter plant was damaged. Reuters reported in October 2024, citing the American Hospital Association, that the plant had been producing 60% of the country's supply of intravenous fluids and peritoneal dialysis solutions. During that crisis, hospitals began postponing scheduled medical procedures that could wait, according to an Associated Press report on the impact of the supply disruption. The postponed procedures included some orthopedic surgeries and cardiac procedures, the agency reported, as hospitals responded to the supply shortage at the time. On August 8, 2025, the U.S. Food and Drug Administration announced the end of the nationwide shortage of 0.9% sodium chloride injection products, saying the shortage of these products had "officially ended."
The implementation timetable Callan JMB outlined in its October 2026 update includes an expected period of about 9 months to manufacture the equipment planned for installation at Atlas. Management said it expects construction of the facility to take between 6 and 9 months, as part of its project estimates. The company assigned the 9-month estimate to the equipment manufacturing phase, while setting a range of 6 to 9 months for facility construction. The implementation process also includes delivery of the equipment to the site and its installation, both of which the company cited as conditions for its targeted production date. Commissioning and validation work would follow, among the requirements for preparing the project for production that Callan JMB outlined in its statement.
Callan JMB targets initial production before the end of 2027, according to the timeline management announced in its campus update. The company made meeting that date conditional on completing construction, equipment delivery and installation, as well as commissioning and validation work. The targeted timetable also requires meeting regulatory requirements before production begins, according to the statement distributed through GlobeNewswire. The date management set applies to the project's initial production, which it included in its plan to develop pharmaceutical manufacturing at Atlas. The end of 2027 remains a target date conditional on completing the implementation stages and regulatory requirements the company listed.